First Trust Advisors LP Has $156.15 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

First Trust Advisors LP lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,463,780 shares of the biopharmaceutical company’s stock after selling 361,927 shares during the quarter. First Trust Advisors LP owned about 0.19% of Gilead Sciences worth $156,154,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Cooper Financial Group lifted its stake in shares of Gilead Sciences by 4.3% in the 2nd quarter. Cooper Financial Group now owns 3,604 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 149 shares during the last quarter. LeJeune Puetz Investment Counsel LLC raised its position in Gilead Sciences by 0.6% during the 3rd quarter. LeJeune Puetz Investment Counsel LLC now owns 26,385 shares of the biopharmaceutical company’s stock worth $1,672,000 after purchasing an additional 155 shares during the last quarter. Alpha Cubed Investments LLC raised its position in shares of Gilead Sciences by 0.6% in the 2nd quarter. Alpha Cubed Investments LLC now owns 25,592 shares of the biopharmaceutical company’s stock worth $1,729,000 after acquiring an additional 156 shares in the last quarter. Blume Capital Management Inc. raised its position in shares of Gilead Sciences by 4.8% in the 2nd quarter. Blume Capital Management Inc. now owns 3,615 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 165 shares in the last quarter. Finally, Perigon Wealth Management LLC raised its position in shares of Gilead Sciences by 0.3% in the 2nd quarter. Perigon Wealth Management LLC now owns 51,335 shares of the biopharmaceutical company’s stock worth $3,468,000 after acquiring an additional 165 shares in the last quarter. 79.91% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on the company. Bank of America assumed coverage on Gilead Sciences in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $70.00 price objective for the company. Citigroup set a $78.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Oppenheimer lowered their price objective on Gilead Sciences from $85.00 to $80.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Guggenheim set a $86.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, Jefferies Financial Group set a $95.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $79.27.

Shares of Gilead Sciences stock traded up $1.42 on Friday, reaching $65.38. 4,952,697 shares of the company traded hands, compared to its average volume of 6,639,517. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $72.90. The company has a 50 day moving average of $64.17 and a 200 day moving average of $65.24. The firm has a market capitalization of $82.81 billion, a PE ratio of 10.63, a PEG ratio of 3.47 and a beta of 1.09. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.06 and a quick ratio of 2.96.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.74 by $0.01. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The firm had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.61 billion. During the same period in the prior year, the firm earned $1.84 EPS. The company’s revenue was up .1% compared to the same quarter last year. As a group, analysts anticipate that Gilead Sciences, Inc. will post 6.66 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.85%. The ex-dividend date is Thursday, December 12th. Gilead Sciences’s dividend payout ratio is currently 40.98%.

In other news, EVP Brett A. Pletcher sold 2,095 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $66.06, for a total transaction of $138,395.70. Following the completion of the transaction, the executive vice president now directly owns 17,826 shares of the company’s stock, valued at approximately $1,177,585.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 5,677 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $63.31, for a total transaction of $359,410.87. Following the transaction, the executive vice president now directly owns 21,521 shares of the company’s stock, valued at $1,362,494.51. The disclosure for this sale can be found here. Insiders have sold a total of 17,288 shares of company stock valued at $1,108,682 over the last three months. Insiders own 0.20% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: What is the QQQ ETF?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply